-

Updated Software Solutions Offer Increased Productivity and Data Confidence

Thermo Scientific software enhancements enable improved usability, efficiency and performance across a wide range of workflows

MINNEAPOLIS--(BUSINESS WIRE)--ASMS 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, has released new software to scientists in biopharmaceutical, proteomics, and small molecule settings to enable more comprehensive analysis of their data. The latest software updates bring new features that enable researchers to extract more information from their new and existing data, streamline data interpretation, and standardize reporting with increased ease of use.

“It’s essential that we continue to develop our software platforms to meet the increasing data analysis needs of our customers, expanding analytical capabilities and providing greater biological insights,” said August Specht, vice president, global research and development, chromatography and mass spectrometry, Thermo Fisher Scientific. “Thanks to the latest upgrades to our software suites, we can give scientists access to the newest technologies and built-for-purpose platforms to quickly and confidently turn data into meaningful results.”

Thermo Fisher Scientific is showcasing these latest software releases during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022 in Booth 400 at the Minneapolis Convention Center, Minneapolis, Minnesota and at the Hilton Minneapolis Grand Ballrooms E, F, G.

A complete solution for confident and streamlined biotherapeutic characterization

The newest Thermo Scientific BioPharma Finder 5.1 software offers a complete solution for oligonucleotide analysis and biotherapeutic characterization workflows, providing increased confidence in results by comprehensively characterizing mass spectrometry data using advanced algorithms. Oligonucleotide-based biotherapeutics present unique challenges for characterization due to their complexity. The new software provides an enhanced suite of built-for-purpose tools to overcome these challenges and meet the needs of this rapidly growing field, quickly and confidently turning complex data into meaningful results. Improvements to the kinetic prediction model for oligonucleotides enable more confident prediction and matching. Improved data review tools and tables offer streamlined review and results reporting of complex oligonucleotide data sets.

Redefining proteomics research capabilities by leveraging artificial intelligence

Proteomics scientists can now benefit from the newest Thermo Scientific Proteome Discoverer 3.0 software in combination with the CHIMERYS intelligent search algorithm by MSAID, leveraging artificial intelligence to more fully interpret data generated by Thermo Scientific Orbitrap mass spectrometers. This innovative approach substantially increases the number of unique peptide identifications, improves protein coverage and quantitation capabilities, and enables scientists to discover more in their data. The new intelligent search algorithm also facilitates higher throughput analysis and wide-isolation window data-dependent acquisition for synergistic performance enhancements. This deeper mining of data expands the ways in which proteomics scientists can acquire and apply their data.

Improving untargeted small molecule workflows with new peak detection and quality algorithms

Small molecule researchers can now leverage a faster and more sensitive peak detection algorithm with the newest Thermo Scientific Compound Discoverer 3.3 software to detect more compounds in less time. Filtering large data sets down to relevant compounds is now easier than ever by using the new peak quality functionality to streamline data processing and review. Improve confidence in compound annotations through MSn spectral tree search capabilities in tandem with the Thermo Scientific mzCloud spectral library to address the most challenging unknown compounds. Compound Discoverer 3.3 software, which has been optimized for processing large datasets and detecting low-abundance compounds, will support scientists in metabolomics, pharmaceutical, environmental, food safety, clinical, and forensics applications to acquire the results they need to drive science forward.

For more information on the Thermo Fisher Scientific solutions exhibited at ASMS 2022, please visit www.thermofisher.com/ASMS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
New Thermo Scientific software enhancements enable improved usability, efficiency and performance across a wide range of workflows.
Release Versions

Contacts

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibco™ Bacto™ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli). As demand for plasmid DNA continues to surge to support expanding gene therapy and mRNA vaccin...

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...
Back to Newsroom